The Elevidys (active substance: delandistrogene moxeparvovec) gene therapy was not approved by the European Medicines Agency (EMA) for the treatment of ambulatory children aged 3‑7 years with Duchenne muscular dystrophy (DMD) because of significant concerns about its demonstrated benefit in that patient population. (European Medicines Agency (EMA))
Here are the key reasons:
Table of Contents
Reasons for Elevidys’ Refusal by the EMA
According to the EMA’s public assessment specific reasons include:
- In the pivotal study (the main evidence submitted), there was no statistically significant improvement in motor‑function (as measured using the North Star Ambulatory Assessment, NSAA) at 12 months between the Elevidys arm and placebo arm. The difference was only 0.65 points on a 34‑point scale, which the EMA concluded “may be due to chance”. (European Medicines Agency (EMA)) Read More: What is North Star Ambulatory Assessment?
- Although the therapy induced expression of a shorter form of the dystrophin protein, the levels of that dystrophin expression could not be reliably linked to meaningful improvements in movement ability. (European Medicines Agency (EMA))
- Even when considering sub‑groups of patients who appeared to respond better, the company could not convincingly show that the treatment provided a clinically meaningful benefit in those groups either. (institut-myologie.org)
- Because the company had applied for a conditional marketing authorisation (CMA), the standard the EMA applies is that there must be a positive benefit‑risk (i.e., evidence of benefit + manageable risk) with some compelling data to support it. The EMA concluded that the benefits have not been sufficiently demonstrated in this context, and so refused the authorisation. (European Medicines Agency (EMA))
Additional context and concerns
- Safety issues: There were also significant safety‑concerns, especially in non‑ambulatory patients. Several deaths from acute liver failure were reported in non‑ambulatory patients receiving Elevidys, trials in that population were paused. (DMDWarrioR) While the refusal by EMA was primarily on efficacy grounds for the ambulatory 3‑7 year‑old population, the safety signal likely weighed into the overall regulatory environment.
- The application submitted to EMA was for ambulatory patients aged 3‑7 years. The design of the trial and the choice of primary endpoint (12‑month change in NSAA) were judged to be insufficient by EMA to demonstrate a meaningful slowing of disease progression in that group. (institut-myologie.org)
- The therapy had been approved in some other territories (e.g., Japan and some Middle East countries) under different regulatory frameworks. (dmdwarrior.com)
- EMA’s opinion (via its Committee for Medicinal Products for Human Use, CHMP) is not legally binding until the European Commission decision, but in practice negative CHMP opinions almost always lead to refusal. (GlobeNewswire)
Summary
Although Elevidys represents a novel gene therapy approach for DMD, the EMA concluded that the submitted evidence did not sufficiently demonstrate that it improves motor‑function in the target ambulatory children (3‑7 years) and that the benefit‑risk ratio was not established for that population. Therefore they recommended refusal of the marketing authorisation. (European Medicines Agency (EMA))
